ArticleParticle and fibre toxicology2026
Exposure to polylactic acid microplastics during puberty increases the risk of skeletal dysplasia by disrupting arachidonic acid metabolism in osteoblasts.
Article in Particle and fibre toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Biodegradable polylactic acid (PLA) plastic is considered to be an effective method to solve the global white pollution caused by petroleum-based plastics. Its wide application in disposable tableware and food packaging has led to the risk of human exposure to PLA microplastics (MPs), but its impact on bone health is unclear. Our study investigated the skeletal developmental toxicity of PLA-MPs at environmentally accessible concentrations in adolescent mice and its potential mechanism. Here we demonstrated that PLA-MPs treatment in adolescent mice showed significant skeletal developmental toxicity, manifested as shortened body length and slowed growth of femur and tibia. Further analysis found that PLA-MPs caused a diminution of epiphyseal plate thickness, a decrement in the count of bone trabeculae, damaged femoral microstructure, and inhibited femoral new bone formation. Notably, PLA-MPs enter osteoblasts and destroy their osteogenic differentiation, resulting in a dose-dependent damage that reduces the formation of calcium nodules. Transcriptome analysis further demonstrated that PLA-MPs exposure was associated with disrupted arachidonic acid metabolism, which may contribute to impaired osteoblast formation, especially Cyp2j5 gene and its downstream metabolite epoxyeicosatrienoic acids were significantly inhibited. Subsequent studies have indicated that Ophiopogonin D (Oph D) can activate Cyp2j5 signal to alleviate PLA-MPs-induced damaged osteoblast differentiation. Furthermore, alleviating impaired differentiation function of osteoblasts using Oph D can significantly improve the reduction of trabecular bone and bone microstructure damage caused by adolescent PLA-MPs exposure. This study not only identifies a potential mechanistic association between PLA-MPs exposure and poor bone development, but also emphasizes the need for targeted interventions to protect bone health in adolescent children and the broader impact on environmental and public health policies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.